Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APREOTCMKTS:BIXTNASDAQ:GTBPOTCMKTS:TDLAF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPREAprea Therapeutics$1.69+0.9%$1.73$1.41▼$5.01$9.27M1.2225,886 shs42,645 shsBIXTBioxytran$0.10-0.7%$0.13$0.06▼$0.23$9.39M1.79125,249 shs82,428 shsGTBPGT Biopharma$3.58+1.1%$2.68$1.72▼$4.10$9.16M1.37244,992 shs56,610 shsTDLAFTBG Diagnostics$0.04-14.0%$0.04$0.01▼$0.13$2.38M-12.386,655 shs3,200 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPREAprea Therapeutics0.00%+2.45%-5.90%-17.89%-58.85%BIXTBioxytran0.00%-3.21%-28.43%-25.23%+9.44%GTBPGT Biopharma0.00%+16.07%+37.74%+64.65%+25.09%TDLAFTBG Diagnostics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPREAprea Therapeutics3.4174 of 5 stars3.54.00.00.01.92.51.3BIXTBioxytranN/AN/AN/AN/AN/AN/AN/AN/AGTBPGT Biopharma1.9575 of 5 stars3.81.00.00.02.70.00.6TDLAFTBG DiagnosticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPREAprea Therapeutics 3.00Buy$15.50817.16% UpsideBIXTBioxytran 0.00N/AN/AN/AGTBPGT Biopharma 3.50Strong Buy$11.00207.26% UpsideTDLAFTBG Diagnostics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TDLAF, BIXT, APRE, and GTBP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/26/2025APREAprea TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$11.00(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPREAprea Therapeutics$1.50M6.23N/AN/A$3.55 per share0.48BIXTBioxytranN/AN/AN/AN/A($0.02) per shareN/AGTBPGT BiopharmaN/AN/AN/AN/A($0.75) per shareN/ATDLAFTBG Diagnostics$2.33M1.02N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPREAprea Therapeutics-$12.96M-$2.37N/AN/AN/A-1,095.02%-68.39%-55.74%8/11/2025 (Estimated)BIXTBioxytran-$2.37M-$0.03N/A∞N/AN/AN/A-2,077.16%N/AGTBPGT Biopharma-$13.16M-$5.69N/AN/AN/AN/A-1,033.08%-223.20%8/13/2025 (Estimated)TDLAFTBG Diagnostics$530KN/A0.00∞N/AN/AN/AN/AN/ALatest TDLAF, BIXT, APRE, and GTBP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025BIXTBioxytranN/A-$0.02N/A-$0.02N/AN/A5/15/2025Q1 2025GTBPGT Biopharma-$0.64-$0.76-$0.12-$0.33N/AN/A5/14/2025Q1 2025APREAprea Therapeutics-$0.6543-$0.66-$0.0057-$0.66N/A$0.16 million4/3/2025Q1 2025BIXTBioxytranN/A-$0.01N/A-$0.01N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPREAprea TherapeuticsN/AN/AN/AN/AN/ABIXTBioxytranN/AN/AN/AN/AN/AGTBPGT BiopharmaN/AN/AN/AN/AN/ATDLAFTBG DiagnosticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPREAprea TherapeuticsN/A5.905.90BIXTBioxytranN/AN/AN/AGTBPGT BiopharmaN/A0.730.73TDLAFTBG DiagnosticsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPREAprea Therapeutics34.19%BIXTBioxytranN/AGTBPGT Biopharma8.15%TDLAFTBG DiagnosticsN/AInsider OwnershipCompanyInsider OwnershipAPREAprea Therapeutics13.63%BIXTBioxytran70.00%GTBPGT Biopharma3.40%TDLAFTBG Diagnostics3.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPREAprea Therapeutics75.53 million4.78 millionNo DataBIXTBioxytran288.99 million26.70 millionNot OptionableGTBPGT Biopharma82.59 million2.50 millionNo DataTDLAFTBG DiagnosticsN/A55.29 millionN/ANot OptionableTDLAF, BIXT, APRE, and GTBP HeadlinesRecent News About These CompaniesGrapevines: Napa Valley College launches Regional Transportation, Distribution & Logistic (TDL) training programJanuary 15, 2022 | napavalleyregister.comNCurtiss-Wright Updates TDL Software Products in Advance of DoD’s Link 16 Cryptographic Modernization Capability MandateJanuary 8, 2022 | newswiretoday.comNGlobal Tunable Diode Laser (TDL) Analyzers Market Growth 2021-2026January 7, 2022 | reportsnreports.comRGlobal and United States Tunable Diode Laser (TDL) Gas Analyzers Market Insights, Forecast to 2027December 23, 2021 | reportsnreports.comRTDL: Week 10 Thursday scores and highlightsNovember 5, 2021 | kplctv.comKRaiders Podcast: TDL Ruggs reaction and mailbagNovember 4, 2021 | msn.comTDL: Week 8 Thursday scores and highlightsOctober 22, 2021 | kplctv.comKRaiders podcast: TDL Week 6 review vs. The BroncosOctober 20, 2021 | msn.comTDL: Week 7 Thursday scores and highlightsOctober 15, 2021 | kplctv.comKTDL: Week 6 Thursday scores and highlightsOctober 8, 2021 | kplctv.comKTDL Thursday scores and highlightsSeptember 24, 2021 | kplctv.comKTBG Diagnostics Ltd.August 20, 2021 | barrons.comTDL Two-A-Days high school football previews scheduleAugust 10, 2021 | kplctv.comKNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTDLAF, BIXT, APRE, and GTBP Company DescriptionsAprea Therapeutics NASDAQ:APRE$1.69 +0.02 (+0.90%) As of 03:59 PM EasternAprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.Bioxytran OTCMKTS:BIXT$0.10 0.00 (-0.66%) As of 03:22 PM EasternBioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was founded in 2008 and is headquartered in Needham, Massachusetts.GT Biopharma NASDAQ:GTBP$3.58 +0.04 (+1.13%) As of 03:54 PM EasternGT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.TBG Diagnostics OTCMKTS:TDLAF$0.04 -0.01 (-14.00%) As of 09/7/2021TBG Diagnostics Limited, a molecular diagnostics company, develops, manufactures, and markets molecular diagnostics kits, instruments, and services in Taiwan and China. It provides ExProbe HLA and HPA kits for human leukocyte antigen (HLA) and human platelet antigens (HPA) allele genotyping, which uses real time polymerase chain reaction (PCR) techniques with sequence specific primers and probes; Morgan SSP HLA kits for determining HLA alleles using PCR techniques with sequence specific primers; HLAssure SBT HLA Kits for transplantation donor selection; and AccuType SBT analysis software to analyze sequences from all ab1 based files. The company also offers Morgan SSPal HLA Typing Analysis Software, a gel result interpretation software; HLA typing services that offer low to high resolution using PCR fragment analysis (SSP) and DNA sequencing (SBT); QPCR Q6000, a six-channel real time PCR instrument; QzNGS NGS that provides high resolution HLA genotyping; and COVID-19 testing kits. It serves clinical labs, blood centers, and bone marrow registry labs. The company was formerly known as Progen Pharmaceuticals Limited and changed its name to TBG Diagnostics Limited in December 2015. TBG Diagnostics Limited was incorporated in 1989 is based in Greenslopes, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher The Top Insider Sells From Q2: Buy, Sell, or Hold? 5 High-Yielding ETFs to Buy and Hold Forever Why BigBear.ai Could Rally 100% and Catch Palantir Soon Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Alphabet’s Waymo and Services Beginning to Feel the Pressure? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
